Treatment Solution Specific to Metastatic Disease: TTX-MC138
Small, non-coding strands of RNA have been identified as a significant player in the pathology of cancer. One of the first miRNAs shown to have aberrant expression in cancer was miR-10b. Since the inaugural study on miR-10b, its role in cancer has been extensively validated, as a master regulator of tumor cell viability and metastasis in a range of cancers, including breast, pancreatic, ovarian, colon, glioblastomas, and others. Clinical evidence demonstrated in >700 peer-reviewed publications over the last ten years supports the link between miR-10b and metastasis across at least 18 cancer indications as well as other diseases.
TransCode’s lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b (miR-10b) with the goal of eliminating metastasis. We believe that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others - 18 in total.
TransCode’s lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b (miR-10b) with the goal of eliminating metastasis. We believe that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others - 18 in total.
A small, non-coding microRNA called miRNA-10b, is shown to be the master regulator of metastasis in a range of solid tumors
Cells in the primary tumor are known to up regulate miRNA-10b which allows metastatic cells to develop, detach and migrate
Metastatic tumor cells are better equipped to safely travel to other parts of the body and develop metastases in organs different from the organ of origin
TransCode's TTX platform delivery system has the potential to treat a variety of tumor indications through effective delivery and targeting
Pre-Clinical Results
Metastatic Breast Cancer
In multiple pre-clinical models of triple-negative breast cancer (TNBC), treatment with low-dose chemotherapy and TTX-MC138 eliminated pre-existing local metastases in 100% of treated animals representative of stage II/III metastatic cancer. In models representative of stage IV metastatic cancer, treatment with low-dose chemotherapy and TTX-MC138 resulted in elimination of distant metastases in 65% of animals treated.
|
Notably, no recurrence of metastases occurred following TTX-MC138 treatment cessation.
|
|
|
Sources: Yoo B, et al. Cancer Res. 2015;75(20):4407-4415; Yoo B, et al. Sci Rep. 2017;7:45060; Figure 11 in S-1 Preclinical results of TTX-MC138 in models of metastatic breast cancer.
Pancreatic Cancer
Positive preclinical results achieved with its lead candidate therapeutic, TTX-MC138, in pancreatic adenocarcinoma.
TTX-MC138, applied as monotherapy, in a murine model of pancreatic adenocarcinoma, showed that forty percent (40%) of animals treated had complete responses, defined as complete regression of disease and long-term survival without recurrence.
TTX-MC138, applied as monotherapy, in a murine model of pancreatic adenocarcinoma, showed that forty percent (40%) of animals treated had complete responses, defined as complete regression of disease and long-term survival without recurrence.
|
Survival
|
miR-10b Inhibiton
|
Clinical Path Forward
A first in human Phase O study with TTX-MC138 is planned for 3Q of 2023, and is expected to be followed by Phase I/II.
More About TTX-MC138
For additional information about our groundbreaking lead investigational candidate, TTX-MC138, see the information sheet below.
|
Other Candidates
Learn more about TransCode's other therapeutic candidates.